Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma

Inclusion Criteria:

• Patients must have biopsy confirmed, cluster of differentiation (CD)20 positive diffuse large B-cell lymphoma, mantel cell, high grade-B-cell or anaplastic large B cell non-Hodgkin lymphoma (NHL); AND bone marrow must show =< 20% CD20+ B-cells with >= 15% cellularity within 42 days of study registration
• Any stage disease is allowed

• Patients must have been previously treated:

  • >= 3rd line if bone marrow transplant (BMT) candidate OR
  • >= 2nd line if not BMT candidate OR
  • >= 2nd relapse for BMT candidate OR
  • >= 1st relapse for non- BMT candidate
• Patients must have a diagnostic quality contrast computed tomography (CT) scan of the chest, abdomen and pelvis OR baseline positron emission tomography (PET)-CT scan performed within 28 days prior to registration
• All patients must have bidimensionally measurable disease with lesions at least 1.5 cm in one dimension all measurable disease must be assessed within 28 days of registration
• For purposes of determining prior drug regimens the following should be used as a standard; radiation therapy counts as 1 treatment, BMT including induction counts as one treatment, radioimmunotherapy is not considered a chemotherapy regimen, rituximab alone is not considered a treatment; all prior therapy must have been completed at least 30 days prior to registration; patients should not have taken valproic acid, or any other histone deacetylase inhibitor (eg., vorinostat, romidepsin), for at least 30 days prior to registration; patients must have recovered from any toxicities related to therapies prior to registration
• Patients must not have clinical evidence of central nervous system involvement by lymphoma, since proposed treatment would not be able to address it adequately; any laboratory (eg., lactate dehydrogenase [LDH]) or radiographic tests performed to access central nervous system (CNS) involvement must be negative and must be performed within 42 days prior to registration
• Patients must have unilateral or bilateral bone marrow biopsy performed within 42 days prior to registration
• Life expectancy of greater than 3 months
• Karnofsky performance status >= 60%
• Leukocytes >= 3,000/mcL
• Absolute neutrophil count >= 1,500/mcL
• Platelets >= 100,000/mcL
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal
• Total bilirubin =< 1.5 X institutional upper limit of normal (unless associated with Gilbert's syndrome)
• Serum creatinine < 2 x institutional upper limit of normal OR
• Measured creatinine clearance >= 60 mL/min
• LDH < 1.50 X institutional upper limit of normal
• Patients must have an electrocardiogram (EKG) with no significant abnormalities within 28 days prior to registration
• The effects of PXD-101 on the developing human fetus at the recommended therapeutic dose are unknown; for this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the patient should inform the treating physician immediately
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Patients who have had chemotherapy or radiotherapy within 30 days (6 weeks for nitrosoureas or mitomycin C) prior to study screening or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
• Prior radioimmunotherapy
• Pregnant or nursing
• Clinical evidence of CNS involvement by lymphoma
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to PXD-101 or Zevalin or other agents used in the study
• Concomitant medication that may cause Torsade de Pointes, i.e. prolongation of the QT interval > 500 msec
• Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension, congestive heart failure related to primary cardiac disease, any condition requiring anti-arrhythmic therapy, ischemic or valvular heart disease, or a myocardial infarction within the past 6 months
• Current long QT syndrome or baseline prolongation of QT/QTcF interval, i.e. demonstration of a QTcF interval > 450 msec
• Clinical evidence of severe peripheral vascular disease, diabetic ulcers or venous stasis ulcers, or history of deep venous or arterial thrombosis within 3 months prior to screening
• Known to be human immunodeficiency virus (HIV) positive or with known acquired immunodeficiency syndrome (AIDS) syndrome
• Patients may not be receiving any other investigational agents